Display options
Cite
Rickels K, Athanasiou M, Reed C, et al. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Per Med. 2009;6(2):217-224doi: 10.2217/17410541.6.2.217.
Rickels, K., Athanasiou, M., Reed, C., Rarey, M., & Klebe, G. (2009). Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Personalized medicine, 6(2), 217-224. https://doi.org/10.2217/17410541.6.2.217
Rickels, Karl, et al. "Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression." Personalized medicine vol. 6,2 (2009): 217-224. doi: https://doi.org/10.2217/17410541.6.2.217
Rickels K, Athanasiou M, Reed C, Rarey M, Klebe G. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Per Med. 2009 Mar;6(2):217-224. doi: 10.2217/17410541.6.2.217. PMID: 29788607.
Copy Download .nbib Format: NLM
Share it on

Per Med. 2009 Mar;6(2):217-224. doi: 10.2217/17410541.6.2.217.

Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression.

Personalized medicine

Karl Rickels, Maria Athanasiou, Carol Reed, Rarey, Klebe

Affiliations

  1. Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, 3535 Market Street, Suite 670, Philadelphia, PA 19104-3309, USA. [email protected].
  2. PGxHealth LLC, CT, USA.

PMID: 29788607 DOI: 10.2217/17410541.6.2.217

Abstract

Vilazodone is a novel antidepressant with a dual mechanism of action that combines selective serotonin reuptake inhibition and partial 5-hydroxytryptamine

Keywords: 5-HT1A agonist; SSRI; biomarker; depression; pharmacogenomics; selective serotonin reuptake inhibitor; vilazodone

Publication Types